Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls

By sjmartinez • March 12, 2024

Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls. EBioMedicine. 2024 Mar 7:105042. doi: 10.1016/j.ebiom.2024.105042. Epub ahead of print. PMID: 38471990.

Tags: Antiviral treatment, clinical trials, covid-19, General Internal Medicine, Mitochondrial antioxidants, Post-exposure prophylaxis, Publications, SARS-CoV-2 infection, Translational research

Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

Nguyen T, Koric A, Chang CE, Barul C, Radoi L, Serraino D, Purdue MP, Kelsey KT, McClean MD, Negri E, Edefonti V, Moysich K, Zhang[...]

Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease

Volkmann ER, Wilhalme H, Tashkin DP, Kim GHJ, Goldin J, Haussmann A, Kuwana M, Roth MD, Assassi S. Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial[...]

Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with

Fansiwala K, Sauk JS. Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD. Dig Dis Sci. 2024 Dec 20.[...]